Which has higher earnings and valuation, LNSR or PAVM?

PAVmed has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44M 1.32 -$34.28M -$0.33 N/A PAVmed $70K 301.71 $400K -$16.05 N/A

Is LNSR or PAVM more profitable?

LENSAR has a net margin of 57.57% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% PAVmed -10,794.64% -126.43% -25.49%

Does the media prefer LNSR or PAVM?

In the previous week, LENSAR and LENSAR both had 2 articles in the media. LENSAR's average media sentiment score of 0.89 equaled PAVmed'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, LUNG or PAVM?

PAVmed has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmonx $90.50M 0.84 -$54M -$1.16 N/A PAVmed $70K 301.71 $400K -$16.05 N/A

Is LUNG or PAVM more profitable?

Pulmonx has a net margin of -55.03% compared to PAVmed's net margin of -10,794.64%. Pulmonx's return on equity of -96.66% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -55.03% -96.66% -38.32% PAVmed -10,794.64% -126.43% -25.49%

Does the media favor LUNG or PAVM?

In the previous week, Pulmonx and Pulmonx both had 2 articles in the media. Pulmonx's average media sentiment score of 1.82 beat PAVmed's score of 0.89 indicating that Pulmonx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OM or PAVM more profitable?

Outset Medical has a net margin of -63.06% compared to PAVmed's net margin of -10,794.64%. Outset Medical's return on equity of -61.67% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets Outset Medical -63.06% -61.67% -28.25% PAVmed -10,794.64% -126.43% -25.49%

Is PAVM or MBOT more profitable?

Microbot Medical has a net margin of 0.00% compared to PAVmed's net margin of -10,794.64%. Microbot Medical's return on equity of -21.87% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -10,794.64% -126.43% -25.49% Microbot Medical N/A -21.87% -20.76%

Do analysts prefer PAVM or HSAQ?

PAVmed currently has a consensus price target of $56.00, suggesting a potential upside of 2,021.21%. Given PAVmed's stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, PAVM or HSAQ?

PAVmed has higher revenue and earnings than Health Sciences Acquisitions Co. 2. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PAVmed $70K 301.71 $400K -$16.05 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

PAVmed (PAVM) Competitors

$2.62 -0.02 (-0.91%)

As of 11:12 AM Eastern

Compare

PAVM vs. LNSR, LUNG, OM, MBOT, and HSAQ

Should you buy PAVmed stock or one of its competitors? PAVmed's main competitors and comparable companies include LENSAR (LNSR), Pulmonx (LUNG), Outset Medical (OM), Microbot Medical (MBOT), and Health Sciences Acquisitions Co. 2 (HSAQ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does PAVmed compare to LENSAR?

LENSAR (NASDAQ:LNSR) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

LENSAR has a net margin of 57.57% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
PAVmed	-10,794.64%	-126.43%	-25.49%

LENSAR has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 65.8% of LENSAR shares are owned by company insiders. Comparatively, 13.4% of PAVmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, LENSAR and LENSAR both had 2 articles in the media. LENSAR's average media sentiment score of 0.89 equaled PAVmed'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENSAR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LENSAR currently has a consensus target price of $11.33, indicating a potential upside of 80.75%. PAVmed has a consensus target price of $56.00, indicating a potential upside of 2,021.21%. Given PAVmed's higher probable upside, analysts plainly believe PAVmed is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PAVmed has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.32	-$34.28M	-$0.33	N/A
PAVmed	$70K	301.71	$400K	-$16.05	N/A

Summary

LENSAR beats PAVmed on 9 of the 13 factors compared between the two stocks.

How does PAVmed compare to Pulmonx?

Pulmonx (NASDAQ:LUNG) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Pulmonx currently has a consensus price target of $7.67, indicating a potential upside of 335.61%. PAVmed has a consensus price target of $56.00, indicating a potential upside of 2,021.21%. Given PAVmed's higher possible upside, analysts clearly believe PAVmed is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PAVmed has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.84	-$54M	-$1.16	N/A
PAVmed	$70K	301.71	$400K	-$16.05	N/A

In the previous week, Pulmonx and Pulmonx both had 2 articles in the media. Pulmonx's average media sentiment score of 1.82 beat PAVmed's score of 0.89 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pulmonx has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 7.5% of Pulmonx shares are held by insiders. Comparatively, 13.4% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pulmonx has a net margin of -55.03% compared to PAVmed's net margin of -10,794.64%. Pulmonx's return on equity of -96.66% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-96.66%	-38.32%
PAVmed	-10,794.64%	-126.43%	-25.49%

Summary

Pulmonx beats PAVmed on 8 of the 14 factors compared between the two stocks.

How does PAVmed compare to Outset Medical?

Outset Medical (NASDAQ:OM) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Outset Medical presently has a consensus price target of $10.00, suggesting a potential upside of 146.31%. PAVmed has a consensus price target of $56.00, suggesting a potential upside of 2,021.21%. Given PAVmed's higher probable upside, analysts clearly believe PAVmed is more favorable than Outset Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, PAVmed had 1 more articles in the media than Outset Medical. MarketBeat recorded 2 mentions for PAVmed and 1 mentions for Outset Medical. Outset Medical's average media sentiment score of 1.79 beat PAVmed's score of 0.89 indicating that Outset Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Outset Medical	Very Positive
PAVmed	Positive

19.9% of PAVmed shares are held by institutional investors. 2.5% of Outset Medical shares are held by insiders. Comparatively, 13.4% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Outset Medical has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market. Comparatively, PAVmed has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Outset Medical has a net margin of -63.06% compared to PAVmed's net margin of -10,794.64%. Outset Medical's return on equity of -61.67% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Outset Medical	-63.06%	-61.67%	-28.25%
PAVmed	-10,794.64%	-126.43%	-25.49%

PAVmed has lower revenue, but higher earnings than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outset Medical	$119.48M	0.64	-$81.65M	-$4.09	N/A
PAVmed	$70K	301.71	$400K	-$16.05	N/A

Summary

Outset Medical beats PAVmed on 8 of the 15 factors compared between the two stocks.

How does PAVmed compare to Microbot Medical?

PAVmed (NASDAQ:PAVM) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 13.4% of PAVmed shares are owned by insiders. Comparatively, 4.7% of Microbot Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Microbot Medical has a net margin of 0.00% compared to PAVmed's net margin of -10,794.64%. Microbot Medical's return on equity of -21.87% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-10,794.64%	-126.43%	-25.49%
Microbot Medical	N/A	-21.87%	-20.76%

PAVmed currently has a consensus target price of $56.00, suggesting a potential upside of 2,021.21%. Microbot Medical has a consensus target price of $6.38, suggesting a potential upside of 525.00%. Given PAVmed's higher possible upside, analysts plainly believe PAVmed is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

PAVmed has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	301.71	$400K	-$16.05	N/A
Microbot Medical	N/A	N/A	-$13.14M	-$0.24	N/A

PAVmed has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, PAVmed had 1 more articles in the media than Microbot Medical. MarketBeat recorded 2 mentions for PAVmed and 1 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.92 beat PAVmed's score of 0.89 indicating that Microbot Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
PAVmed	Positive
Microbot Medical	Positive

Summary

Microbot Medical beats PAVmed on 8 of the 14 factors compared between the two stocks.

How does PAVmed compare to Health Sciences Acquisitions Co. 2?

PAVmed (NASDAQ:PAVM) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

PAVmed has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	301.71	$400K	-$16.05	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

PAVmed currently has a consensus price target of $56.00, suggesting a potential upside of 2,021.21%. Given PAVmed's stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PAVmed has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to PAVmed's net margin of -10,794.64%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-10,794.64%	-126.43%	-25.49%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 13.4% of PAVmed shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, PAVmed had 2 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 2 mentions for PAVmed and 0 mentions for Health Sciences Acquisitions Co. 2. PAVmed's average media sentiment score of 0.89 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that PAVmed is being referred to more favorably in the media.

Company	Overall Sentiment
PAVmed	Positive
Health Sciences Acquisitions Co. 2	Neutral

Summary

PAVmed beats Health Sciences Acquisitions Co. 2 on 8 of the 13 factors compared between the two stocks.

Get PAVmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAVM vs. The Competition

Export

Metric	PAVmed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$20.93M	$5.52B	$7.25B	$13.04B
Dividend Yield	N/A	1.75%	2.52%	22.89%
P/E Ratio	-0.16	25.48	275.44	25.51
Price / Sales	298.97	66.54	562.05	79.58
Price / Cash	N/A	32.25	77.16	53.04
Price / Book	-1.08	5.81	10.64	6.00
Net Income	$400K	$146.14M	$3.49B	$380.50M
7 Day Performance	-4.53%	-1.66%	-3.21%	-3.35%
1 Month Performance	-40.41%	-4.35%	-7.65%	-6.23%
1 Year Performance	-83.80%	0.80%	2.92%	-3.96%

PAVmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAVM PAVmed	2.5165 of 5 stars	$2.62 -0.9%	$56.00 +2,040.7%	-84.2%	$20.93M	$70K	N/A	41
LNSR LENSAR	2.3167 of 5 stars	$6.70 +0.4%	$11.33 +69.2%	-47.6%	$81.95M	$58.44M	N/A	150
LUNG Pulmonx	3.4826 of 5 stars	$1.78 -5.3%	$7.67 +330.7%	+10.7%	$80.74M	$90.50M	N/A	296	News Coverage Positive News Gap Up
OM Outset Medical	3.6098 of 5 stars	$4.14 +1.0%	$10.00 +141.5%	-67.8%	$77.07M	$119.48M	N/A	310	Positive News
MBOT Microbot Medical	3.2642 of 5 stars	$1.07 flat	$6.38 +495.8%	-66.1%	$71.87M	N/A	N/A	22	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAVM) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PAVmed (PAVM) Competitors

PAVM vs. LNSR, LUNG, OM, MBOT, and HSAQ

How does PAVmed compare to LENSAR?

Summary

How does PAVmed compare to Pulmonx?

Summary

How does PAVmed compare to Outset Medical?

Summary

How does PAVmed compare to Microbot Medical?

Summary

How does PAVmed compare to Health Sciences Acquisitions Co. 2?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM vs. The Competition

PAVmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PAVmed (PAVM) Competitors

PAVM vs. LNSR, LUNG, OM, MBOT, and HSAQ

How does PAVmed compare to LENSAR?

Is LNSR or PAVM more profitable?

Which has more risk and volatility, LNSR or PAVM?

Do insiders & institutionals believe in LNSR or PAVM?

Does the media prefer LNSR or PAVM?

Do analysts recommend LNSR or PAVM?

Which has higher earnings and valuation, LNSR or PAVM?

Summary

How does PAVmed compare to Pulmonx?

Do analysts rate LUNG or PAVM?

Which has stronger earnings and valuation, LUNG or PAVM?

Does the media favor LUNG or PAVM?

Which has more volatility & risk, LUNG or PAVM?

Do institutionals and insiders believe in LUNG or PAVM?

Is LUNG or PAVM more profitable?

Summary

How does PAVmed compare to Outset Medical?

Do analysts rate OM or PAVM?

Does the media prefer OM or PAVM?

Do institutionals & insiders have more ownership in OM or PAVM?

Which has more risk and volatility, OM or PAVM?

Is OM or PAVM more profitable?

Which has higher valuation and earnings, OM or PAVM?

Summary

How does PAVmed compare to Microbot Medical?

Do insiders & institutionals hold more shares of PAVM or MBOT?

Is PAVM or MBOT more profitable?

Do analysts rate PAVM or MBOT?

Which has better valuation & earnings, PAVM or MBOT?

Which has more volatility and risk, PAVM or MBOT?

Does the media refer more to PAVM or MBOT?

Summary

How does PAVmed compare to Health Sciences Acquisitions Co. 2?

Which has higher valuation and earnings, PAVM or HSAQ?

Do analysts prefer PAVM or HSAQ?

Which has more volatility and risk, PAVM or HSAQ?

Is PAVM or HSAQ more profitable?

Do insiders and institutionals hold more shares of PAVM or HSAQ?

Does the media favor PAVM or HSAQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM vs. The Competition

PAVmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools